Vericel

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vericel (VCEL) reports robust Q4 earnings and eyes market expansion

Vericel (VCEL) closed 2022 with strong financial and business results, setting the stage for continued growth and profitability in 2023.
The company's focus on innovation, market expansion, and financial discipline underscores its commitment to long-term success.
Despite challenges in regulatory approvals and operational timelines, Vericel (VCEL) remains optimistic about its growth prospects and market positioning.

Vericel reports robust Q1 earnings, raises revenue guidance significantly

Vericel's Q1 performance reflects resilience and growth, with a focus on expanding revenue streams and market presence through product development and commercialization efforts.
While facing challenges in managing expenses and achieving profitability, the company's strong financial position and revenue guidance revisions signal confidence in its growth trajectory.
By capitalizing on MACI's success, navigating upcoming product launches, and maintaining financial discipline, Vericel is poised for continued success and market expansion in the regenerative medicine space.

Vericel reports robust Q2 earnings, eyes growth through new products

Vericel's strong Q2 performance and raised revenue guidance indicate a positive outlook for the company.
Challenges with NexoBrid distribution and MACI conversion rates require focused strategies for growth.
Opportunities lie in upcoming product launches and targeted sales approaches to drive revenue growth.

Vericel reports record Q3 revenue, raises guidance for 2023

Vericel's Q3 performance was exceptional, setting the stage for continued growth.
The company's strong financial position and product strategies bode well for future success.
Anticipated revenue growth in 2024 and expansion plans signal positive momentum.
Vericel aims for a robust finish in 2023 and sustained growth in 2024.

Vericel (VCEL) posts record Q4 revenue, eyes sustained growth

Vericel (VCEL) delivered robust financial results in Q4 2023, with strong revenue growth, operational efficiency, and positive market feedback on key products.
The company is well-positioned for future growth with new product launches, improved margins, and resolved customer dynamics enhancing market stability.
While challenges exist in maintaining growth momentum and managing quarterly margins, strategic investments and market opportunities offer avenues for sustained success.

Vericel (VCEL) posts stellar Q1 results, eyes market expansion

Vericel delivered a robust performance in Q1 2024, marked by revenue growth, profitability surge, and raised full-year guidance.
The company's strengths lie in margin expansion efforts, strategic investments, and plans for market expansion through new initiatives and surgeon targeting.
Challenges include balancing expenses with profitability targets and ensuring rapid adoption of new products among diverse surgeon segments.
Opportunities abound in operational efficiencies, market expansion strategies, and potential for accelerated growth based on product advantages and market positioning.

Vericel reports record Q2 revenue, eyes growth through new launches

Vericel delivered a strong performance in Q2 2024 with record revenue and profitability, driven by MACI and operational efficiency.
While facing challenges with Epicel revenue variability, the company remains optimistic about growth opportunities and market expansion.
With a focus on product launches, FDA approvals, and financial strength, Vericel is well-positioned for continued growth and success in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2022 financial results on Wednesday, November 9, 2022. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results and certain business highlights.

Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief Financial Officer Joe Mara will present at the upcoming Ladenburg Thalmann Healthcare Conference. The presentation is scheduled to begin at 2:30 p.m. ET on Thursday, September 29, 2022.

Vericel to Present at the Ladenburg Thalmann Healthcare Conference

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Morgan Stanley and H.C. Wainwright investor conferences.

Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences

The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Vericel Corporation (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Vericel Corporation (VCEL)? Wall Street Analysts Think 53%

Vericel Corporation (NASDAQ:VCEL ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investor Relations Nick Colangelo - President & Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Sam Bedovsky - Truist Jeffrey Cohen - Ladenburg Thalmann Arthur He - HCW Operator Ladies and gentlemen, thank you for standing by. Welcome to the Vericel's Second Quarter 2022 Conference Call.

Vericel Corporation (VCEL) CEO Nick Colangelo on Q2 2022 Results - Earnings Call Transcript

Second Quarter Total Net Revenue of $37.0 Million

Vericel Reports Second Quarter 2022 Financial Results

CAMBRIDGE, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the publication of results from a retrospective study conducted by the Burn and Reconstructive Centers of America (BRCA) of 40 patients with large posterior trunk burns treated with Epicel® (cultured epidermal autografts) in the Journal of Burn Care & Research . Severe burns on posterior trunk surfaces present special consideration since the posterior surfaces bear the major portion of the body weight. The study evaluated the success of engraftment in patients receiving Epicel for posterior trunk burns with total burn surface area (TBSA) ≥30% treated at three high-volume burn centers within the BRCA between March 2016 and December 2019.

Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel

CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2022 financial results on Wednesday, August 3, 2022. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results and business highlights.

Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022

Vericel Corp (NASDAQ:VCEL ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Eric Burns - Executive Director, Financial Planning and Analysis & IR Dominick Colangelo - CEO, President & Director Joseph Mara - CFO & Treasurer Conference Call Participants Ryan Zimmerman - BTIG Christopher Cooley - Stephens Inc. Jeffrey Cohen - Ladenburg Thalmann & Co. Danielle Antalffy - SVB Leerink Samuel Brodovsky - Truist Securities Arthur He - H.C. Wainwright & Co. Operator Ladies and gentlemen, thank you for standing by.

Vericel Corp (VCEL) CEO Dominick Colangelo on Q1 2022 Results - Earnings Call Transcript

First Quarter Total Net Revenue of $36.1 Million

Vericel Reports First Quarter 2022 Financial Results

CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2022 financial results and business highlights.

Vericel to Report First-Quarter 2022 Financial Results on May 4, 2022

The NexoBrid complete response letter sparked a market overreaction on Vericel Corporation stocks. Coupled with the 2021/2022 Biotech Bear market, Vericel shares are trading at a deep bargain to their intrinsic value.

Vericel: Poised For Growth

Vericel is a high growth, disruptive medical technology company with average 5-year sales growth of 24%.

Vericel - A Disruptive Business With Years Of Growth Remaining

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Musculoskeletal Conference in Chicago, IL on Tuesday, March 22nd at 11:00 a.m. Central Time.

Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022

CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9th at 1:30 p.m. Eastern Time.

Vericel to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022

CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Board of Directors has appointed Jonathan Siegal as the Company's Principal Accounting Officer, effective February 16, 2022. Mr. Siegal is currently serving as Vericel's Vice President and Corporate Controller.

Vericel Announces Appointment of Jonathan Siegal as Principal Accounting Officer

Vericel Corporation (VCEL) CEO Nick Colangelo on Q4 2021 Results - Earnings Call Transcript

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -47.06% and 0.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Q4 Earnings Miss Estimates

Full-Year 2021 Total Revenue Growth of 26%

Vericel Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Full-Year 2022 Financial Guidance

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Vericel Corporation (VCEL) Q4 Earnings Expected to Decline

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2021 financial results and business highlights.

Vericel to Report Fourth-Quarter 2021 Financial Results on February 24, 2022

CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it has entered into a long-term lease agreement for a new state-of-the-art advanced cell therapy manufacturing and corporate headquarters facility at the Network Drive campus at Northwest Park in Burlington, Massachusetts.

Vericel Announces Plans for a New State-of-the-Art Cell Therapy Manufacturing Facility to Support Long-Term Growth

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 7:30 a.m. Eastern Time.

Vericel to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

The 2021 Biotech Bear market is creating a huge investment opportunity, as fundamentally robust companies are trading at a deep bargain. With its two powerful cellular therapies, Vericel is enjoying significant revenue increases year over year.

Vericel: In The Middle Of Difficulty Is An Opportunity

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on Thursday November 18th, at 10:00a.m. Eastern Time.

News for Vericel Stock (VCEL)